Maze Therapeutics, Inc.
MAZE
$7.83
$0.233.03%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 52.23M | 55.23M | 55.24M | -22.59M | -100.42M |
| Total Depreciation and Amortization | 3.30M | 3.57M | 3.78M | 3.94M | 4.09M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 21.95M | 23.76M | 20.58M | 18.20M | 15.82M |
| Change in Net Operating Assets | -1.52M | -4.80M | 1.39M | -2.46M | -6.32M |
| Cash from Operations | 75.95M | 77.76M | 81.00M | -2.92M | -86.83M |
| Capital Expenditure | -1.15M | -576.00K | -470.00K | -455.50K | -441.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1.15M | -576.00K | -470.00K | -455.50K | -441.00K |
| Total Debt Issued | 24.48M | 40.65M | 40.65M | 28.41M | 16.18M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 733.00K | 682.00K | 464.00K | 336.50K | 209.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 70.79M | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.15M | -2.56M | -184.00K | -92.00K | -- |
| Cash from Financing | 92.85M | 38.77M | 40.93M | 28.66M | 16.39M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 167.65M | 115.96M | 121.46M | 25.29M | -70.88M |